SCHEMBL985849

SCHEMBL985849

COc1cc(C)cc(C(=O)Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ATM Q13315 1/20 0.41
TPMT P51580 1/20 0.40
KDM4E B2RXH2 2/20 0.40
KCNK3 O14649 1/20 0.40
KCNK9 Q9NPC2 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PARP1 P09874 1/20 0.39
CYP3A4 P08684 1/20 0.39
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24155 0.87 ALDH1A1 (0.52) CES2CES1MEN1KMT2ANPC1
SCHEMBL3361585 0.87 CES2 (0.47) CES2CES1MEN1KMT2AKDM4E
SCHEMBL12020820 0.82 LMNA (0.48) CES2CES1MEN1KMT2ANPC1
SCHEMBL11914196 0.82 ALDH1A1 (0.46) CES2CES1MEN1KMT2ANPC1
SCHEMBL6738707 0.82 TPMT (0.64) CES2CES1MEN1KMT2ATPMT
SCHEMBL10148964 0.81 LMNA (0.50) MEN1KMT2ATPMTKDM4EGAA
SCHEMBL4360630 0.80 TPMT (0.52) CES2CES1ATMTPMTALDH1A1
SCHEMBL347092 0.80 TPMT (0.59) MEN1KMT2ATPMTGAAALDH1A1
SCHEMBL24653922 0.80 BACE1 (0.46) CES2CES1MEN1KMT2ANPC1
SCHEMBL19828394 0.80 PARP1 (0.56) CES2CES1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160060254-A1 THIAZOLE-BASED INHIBITORS OF SCAVENGER RECEPTOR BI THE BROAD INSTITUTE, INC. 2016-03-03 US disclosed
US-20120172339-A1 ANGIOGENIC RESORCINOL DERIVATIVES NORTHEASTERN UNIVERSITY (US) 2012-07-05 US disclosed
US-7875631-B2 e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed ANALYTECON S.A. (CH) 2011-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172339-A1 ANGIOGENIC RESORCINOL DERIVATIVES CNR1, CNR2, KDR CES2 783/4885CES1 653/4885MEN1 3629/4885
US-20160060254-A1 THIAZOLE-BASED INHIBITORS OF SCAVENGER RECEPTOR BI SCARB1, HAVCR2, LDLR CES2 302/4885CES1 31/4885MEN1 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.